Outcome after Discontinuation of Second Generation Tyrosine Kinase Inhibitors (TKIs) Used As Frontline Therapy for Patients (pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML)

被引：0
|
作者：
Abdelall, Waleed
Kantarjian, Hagop M.
Devendra, K. C.
Akosile, Mary
Borthakur, Gautam
Verstovsek, Srdan
Daver, Naval
Pemmaraju, Naveen
Naqvi, Kiran
Garcia-Manero, Guillermo
Thompson, Philip A.
Ferrajoli, Alessandra
Ravandi, Farhad
Konopleva, Marina
DiNardo, Courtney D.
Jabbour, Elias J.
Cortes, Jorge E.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5248
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors
    Aoki, Jun
    Ohashi, Kazuteru
    Kobayashi, Takeshi
    Kakihana, Kazuhiko
    Hirashima, Yuka
    Sakamaki, Hisashi
    LEUKEMIA & LYMPHOMA, 2012, 53 (07) : 1412 - 1414
  • [42] Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP)
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    Luthra, Rajyalakshmi
    O'Brien, Susan
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Borthakur, Gautam
    Ravandi, Farhad
    Verstovsek, Srdan
    Burton, Elizabeth
    Walker, Brenda
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 740 - 741
  • [43] Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    O'Brien, Susan
    Borthakur, Gautam
    Ravandi, Farhad
    Verstovsek, Srdan
    Daver, Naval G.
    Garcia-Manero, Guillermo
    DiNardo, Courtney D.
    Skinner, Jeff
    Konopleva, Marina
    Pierce, Sherry
    Jabbour, Elias
    Cortes, Jorge E.
    BLOOD, 2014, 124 (21)
  • [44] Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
    Jabbour, Elias
    Kantarjian, Hagop
    O'Brien, Susan
    Shan, Jenny
    Garcia-Manero, Guillermo
    Wierda, William
    Ravandi, Farhad
    Borthakur, Gautam
    Rios, Mary Beth
    Cortes, Jorge
    BLOOD, 2011, 117 (06) : 1822 - 1827
  • [45] A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs).
    Mauro, Michael J.
    Hochhaus, Andreas
    Boquimpani, Carla
    Minami, Yosuke
    Allepuz, Alex
    Polydoros, Fotis
    Bedoucha, Veronique
    Aimone, Paola
    Rea, Delphine
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study
    Mauro, Michael
    Hochhaus, Andreas
    Hughes, Timothy
    Rea, Delphine
    Boquimpani, Carla
    Minami, Yosuke
    Apperley, Jane
    Garcia-Gutierrez, Valentin
    Kapoor, Shruti
    Espurz, Noemi
    Dhamal, Vishal
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S340 - S340
  • [47] Incidence and Outcomes of Chronic Myeloid Leukemia (CML) Patients (pts) with Other Chromosomal Abnormalities (OCA) Treated with Second Generation Tyrosine Kinase Inhibitors (TKI)
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    Jabbour, Elias J.
    Quintas-Cardama, Alfonso
    Borthakur, Gautam
    Burton, Elizabeth M.
    Dellasala, Sara E.
    Pierce, Sherry A.
    Kornblau, Steven M.
    Verstovsek, Srdan
    O'Brien, Susan
    Cortes, Jorge E.
    BLOOD, 2012, 120 (21)
  • [48] Comparison of the Outcome between Newly Diagnosed Patients in the Accelerated Phase and Chronic Phase with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors
    Jiang, Qian
    Yu, Lu
    Qin, Ya-Zhen
    Lai, Yue-Yun
    Huang, Xiao-Jun
    BLOOD, 2017, 130
  • [49] Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies
    Verma, Dushyant
    Kantarjian, Hagop
    Strom, Sara S.
    Rios, Mary Beth
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Verstovsek, Srdan
    Ravandi, Farhad
    O'Brien, Susan
    Cortes, Jorge
    BLOOD, 2011, 118 (16) : 4353 - 4358
  • [50] Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs).
    Nicolini, Franck E.
    Lipton, Jeffrey Howard
    Kantarjian, Hagop
    Wetzler, Meir
    Akard, Luke Paul
    Baccarani, Michele
    Craig, Adam
    Nanda, Nisha
    Brown, Peter D.
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345